Literature DB >> 20191495

A modified Sharp score demonstrates disease progression in established psoriatic arthritis.

J Ravindran1, C Cavill, C Balakrishnan, S M Jones, E Korendowych, N J McHugh.   

Abstract

OBJECTIVE: To use a modified Sharp score (MSS) to measure radiologic progression and to assess its relationship to other radiologic features, peripheral joint disease, and physical function in psoriatic arthritis (PsA).
METHODS: Two sets of hand radiographs (median interval 5.75 years) in 139 patients with established PsA were scored using an MSS. Seventy-four patients had standardized clinical joint and Health Assessment Questionnaire (HAQ) scores and other radiologic features of PsA documented at baseline and followup (median interval 5 years).
RESULTS: Radiologic damage was present in 58% of patients at baseline and 74% at followup. The median MSS and its components, erosion score and joint space abnormality score, were significantly greater at followup (P < 0.001). The median MSS progression was +1.08 units/year. There was strong correlation between MSS and clinical joint scores at baseline and followup (r = 0.72 and r = 0.81, respectively). There was weak correlation between MSS and HAQ at baseline (r = 0.29), but stronger correlation at followup (r = 0.48). There was a strong association between MSS and other characteristic radiologic features of PsA (bony proliferation, periostitis, bony ankylosis) at baseline and followup (P < 0.001). However, the presence of soft-tissue swelling on radiographs at baseline was the only radiologic parameter associated with an increased rate of change of MSS (corrected P < 0.006).
CONCLUSION: The MSS shows good construct validity with measures of peripheral joint involvement such as clinical joint scores and other radiologic features of PsA, and is able to demonstrate that radiologic damage is progressive beyond early disease.

Entities:  

Mesh:

Year:  2010        PMID: 20191495     DOI: 10.1002/acr.20018

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  6 in total

Review 1.  Treatment algorithms for early psoriatic arthritis: do they depend on disease phenotype?

Authors:  William Tillett; Neil McHugh
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 2.  Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.

Authors:  Angela Mc Ardle; Brian Flatley; Stephen R Pennington; Oliver FitzGerald
Journal:  Arthritis Res Ther       Date:  2015-06-01       Impact factor: 5.156

3.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Authors:  Josef S Smolen; Monika Schöls; Jürgen Braun; Maxime Dougados; Oliver FitzGerald; Dafna D Gladman; Arthur Kavanaugh; Robert Landewé; Philip Mease; Joachim Sieper; Tanja Stamm; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Neil Betteridge; Filip van den Bosch; Laura C Coates; Paul Emery; Lianne S Gensler; Laure Gossec; Philip Helliwell; Merryn Jongkees; Tore K Kvien; Robert D Inman; Iain B McInnes; Mara Maccarone; Pedro M Machado; Anna Molto; Alexis Ogdie; Denis Poddubnyy; Christopher Ritchlin; Martin Rudwaleit; Adrian Tanew; Bing Thio; Douglas Veale; Kurt de Vlam; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

4.  A Comparative Study of High-Resolution Chemical-Shift-Eliminated Magnetic Resonance Imaging of Finger Specimens with Microcomputed Tomography.

Authors:  Wingchi Edmund Kwok; Zhigang You; Johnny Monu; Hua He
Journal:  J Clin Imaging Sci       Date:  2019-05-24

5.  Radiographic development during three decades in a patient with psoriatic arthritis mutilans.

Authors:  Leena Laasonen; Björn Gudbjornsson; Leif Ejstrup; Lars Iversen; Thomas Ternowitz; Mona Ståhle; Ulla Lindqvist
Journal:  Acta Radiol Open       Date:  2015-07-06

6.  Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways.

Authors:  Wei Shang; Ling-Jie Zhao; Xiao-Lei Dong; Zhi-Ming Zhao; Jing Li; Bei-Bei Zhang; Hui Cai
Journal:  Mol Med Rep       Date:  2016-08-25       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.